Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Modifiable risk factors for permanent pacemaker after transcatheter aortic valve implantation: CONDUCT registry

T. Rudolph, M. Droppa, J. Baan, NE. Nielsen, J. Baranowski, V. Hachaturyan, J. Kurucova, L. Hack, P. Bramlage, T. Geisler

. 2023 ; 10 (1) : . [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004281

OBJECTIVE: The onset of new conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) is still a relevant adverse event. The main objective of this registry was to identify modifiable procedural risk factors for an improved outcome (lower rate of PPI) after TAVI in patients at high risk of PPI. METHODS: Patients from four European centres receiving a balloon-expandable TAVI (Edwards SAPIEN 3/3 Ultra) and considered at high risk of PPI (pre-existing conduction disturbance, heavily calcified left ventricular outflow tract or short membranous septum) were prospectively enrolled into registry. RESULTS: A total of 300 patients were included: 42 (14.0%) required PPI after TAVI and 258 (86.0%) did not. Patients with PPI had a longer intensive care unit plus intermediate care stay (65.7 vs 16.3 hours, p<0.001), general ward care stay (6.9 vs 5.3 days, p=0.004) and later discharge (8.6 vs 5.0 days, p<0.001). Of the baseline variables, only pre-existing right bundle branch block at baseline (OR 6.8, 95% CI 2.5 to 18.1) was significantly associated with PPI in the multivariable analysis. Among procedure-related variables, oversizing had the highest impact on the rate of PPI: higher than manufacturer-recommended sizing, mean area oversizing as well as the use of the 29 mm valve (OR 3.4, 95% CI 1.4 to 8.5, p=0.008) all were significantly associated with PPI. Rates were higher with the SAPIEN 3 (16.1%) vs SAPIEN 3 Ultra (8.5%), although not statistically significant but potentially associated with valve sizing. Implantation depth and postdelivery balloon dilatation also tended to affect PPI rates but without a statistical significance. CONCLUSION: Valve oversizing is a strong procedure-related risk factor for PPI following TAVI. The clinical impact of the valve type (SAPIEN 3), implantation depth, and postdelivery balloon dilatation did not reach significance and may reflect already refined procedures in the participating centres, giving attention to these avoidable risk factors. TRIAL REGISTRATION NUMBER: NCT03497611.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004281
003      
CZ-PrNML
005      
20230425141247.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/openhrt-2022-002191 $2 doi
035    __
$a (PubMed)36750275
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rudolph, Tanja $u Department of Cardiology, Cologne University, Cologne, Germany $u Clinic for General and Interventional Cardiology/Angiology, Ruhr University Bochum, Bochum, Germany
245    10
$a Modifiable risk factors for permanent pacemaker after transcatheter aortic valve implantation: CONDUCT registry / $c T. Rudolph, M. Droppa, J. Baan, NE. Nielsen, J. Baranowski, V. Hachaturyan, J. Kurucova, L. Hack, P. Bramlage, T. Geisler
520    9_
$a OBJECTIVE: The onset of new conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) is still a relevant adverse event. The main objective of this registry was to identify modifiable procedural risk factors for an improved outcome (lower rate of PPI) after TAVI in patients at high risk of PPI. METHODS: Patients from four European centres receiving a balloon-expandable TAVI (Edwards SAPIEN 3/3 Ultra) and considered at high risk of PPI (pre-existing conduction disturbance, heavily calcified left ventricular outflow tract or short membranous septum) were prospectively enrolled into registry. RESULTS: A total of 300 patients were included: 42 (14.0%) required PPI after TAVI and 258 (86.0%) did not. Patients with PPI had a longer intensive care unit plus intermediate care stay (65.7 vs 16.3 hours, p<0.001), general ward care stay (6.9 vs 5.3 days, p=0.004) and later discharge (8.6 vs 5.0 days, p<0.001). Of the baseline variables, only pre-existing right bundle branch block at baseline (OR 6.8, 95% CI 2.5 to 18.1) was significantly associated with PPI in the multivariable analysis. Among procedure-related variables, oversizing had the highest impact on the rate of PPI: higher than manufacturer-recommended sizing, mean area oversizing as well as the use of the 29 mm valve (OR 3.4, 95% CI 1.4 to 8.5, p=0.008) all were significantly associated with PPI. Rates were higher with the SAPIEN 3 (16.1%) vs SAPIEN 3 Ultra (8.5%), although not statistically significant but potentially associated with valve sizing. Implantation depth and postdelivery balloon dilatation also tended to affect PPI rates but without a statistical significance. CONCLUSION: Valve oversizing is a strong procedure-related risk factor for PPI following TAVI. The clinical impact of the valve type (SAPIEN 3), implantation depth, and postdelivery balloon dilatation did not reach significance and may reflect already refined procedures in the participating centres, giving attention to these avoidable risk factors. TRIAL REGISTRATION NUMBER: NCT03497611.
650    _2
$a lidé $7 D006801
650    12
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a kardiostimulace umělá $x škodlivé účinky $x metody $7 D002304
650    12
$a srdeční chlopně umělé $x škodlivé účinky $7 D006350
650    12
$a kardiostimulátor $7 D010138
650    _2
$a registrace $7 D012042
650    _2
$a rizikové faktory $7 D012307
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $7 D065467
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Droppa, Michal $u Department of Cardiology and Angiology, University Hospital Tübingen, Tubingen, Baden-Württemberg, Germany $1 https://orcid.org/0000000158077615
700    1_
$a Baan, Jan $u Heart Center, University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands
700    1_
$a Nielsen, Niels-Erik $u Department of Cardiology, Linköping University Hospital, Linköping, Sweden
700    1_
$a Baranowski, Jacek $u Department of Cardiology, Linköping University Hospital, Linköping, Sweden
700    1_
$a Hachaturyan, Violetta $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic
700    1_
$a Hack, Luis $u Department of Cardiology, Cologne University, Cologne, Germany
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany peter.bramlage@ippmed.de
700    1_
$a Geisler, Tobias $u Department of Cardiology and Angiology, University Hospital Tübingen, Tubingen, Baden-Württemberg, Germany
773    0_
$w MED00186378 $t Open heart $x 2053-3624 $g Roč. 10, č. 1 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36750275 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141244 $b ABA008
999    __
$a ok $b bmc $g 1924761 $s 1190490
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 10 $c 1 $e - $i 2053-3624 $m Open heart $n Open Heart $x MED00186378
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace